An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma-Reference-Cited by-同舟云学术

An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma

Published:2023-12-05 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Li Manjun¹^ORCID,Bennett Melissa K.¹^ORCID,Toubia John¹^ORCID,Pope Victoria S.¹^ORCID,Tea Melinda N.¹^ORCID,Tamang Sarah¹,Samuel Michael S.¹²^ORCID,Anderson Paul H.³^ORCID,Gliddon Briony L.¹^ORCID,Powell Jason A.¹²^ORCID,Pitson Stuart M.¹⁴^ORCID

Affiliation:

1. Centre for Cancer Biology University of South Australia and SA Pathology Adelaide South Australia Australia

2. Adelaide Medical School University of Adelaide Adelaide South Australia Australia

3. Clinical and Health Sciences University of South Australia Adelaide South Australia Australia

4. School of Biological Sciences University of Adelaide Adelaide South Australia Australia

Abstract

SummaryWhile bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM.

Funder

Fay Fuller Foundation

National Health and Medical Research Council

Royal Adelaide Hospital Research Fund

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19240

Reference15 articles.

1. Resistance to proteasome inhibitors and other targeted therapies in myeloma

2. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

3. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

4. Emerging therapies for multiple myeloma

5. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy